190 related articles for article (PubMed ID: 38538691)
1. Potential diagnostic and drug target markers in glioblastoma.
Ahsan H; Asghar M; Malik SI
Sci Rep; 2024 Mar; 14(1):7292. PubMed ID: 38538691
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma.
Cheng W; Zhang C; Ren X; Jiang Y; Han S; Liu Y; Cai J; Li M; Wang K; Liu Y; Hu H; Li Q; Yang P; Bao Z; Wu A
J Neurosurg; 2017 Jan; 126(1):249-259. PubMed ID: 26967788
[TBL] [Abstract][Full Text] [Related]
3. An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential
Mokgautsi N; Wen YT; Lawal B; Khedkar H; Sumitra MR; Wu ATH; Huang HS
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33671112
[TBL] [Abstract][Full Text] [Related]
4. GCSF deficiency attenuates nonalcoholic fatty liver disease through regulating GCSFR-SOCS3-JAK-STAT3 pathway and immune cells infiltration.
Zhang Y; Zhou X; Liu P; Chen X; Zhang J; Zhang H; Li S; Chen Y; Song X; Wang J; Zeng H; Zhang X; Tang C; Yu C; Li Y; Xu C
Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G531-G542. PubMed ID: 33470903
[TBL] [Abstract][Full Text] [Related]
5. Identification of potential crucial genes and molecular mechanisms in glioblastoma multiforme by bioinformatics analysis.
Chen X; Pan Y; Yan M; Bao G; Sun X
Mol Med Rep; 2020 Aug; 22(2):859-869. PubMed ID: 32467990
[TBL] [Abstract][Full Text] [Related]
6. RCC2 promotes proliferation and radio-resistance in glioblastoma via activating transcription of DNMT1.
Yu H; Zhang S; Ibrahim AN; Wang J; Deng Z; Wang M
Biochem Biophys Res Commun; 2019 Aug; 516(3):999-1006. PubMed ID: 31277942
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3.
Ventero MP; Fuentes-Baile M; Quereda C; Perez-Valeciano E; Alenda C; Garcia-Morales P; Esposito D; Dorado P; Manuel Barbera V; Saceda M
PLoS One; 2019; 14(2):e0212581. PubMed ID: 30811476
[TBL] [Abstract][Full Text] [Related]
8. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
[TBL] [Abstract][Full Text] [Related]
9. Piperlongumine-inhibited TRIM14 signaling sensitizes glioblastoma cells to temozolomide treatment.
Kuo YY; Ho KH; Shih CM; Chen PH; Liu AJ; Chen KC
Life Sci; 2022 Nov; 309():121023. PubMed ID: 36202175
[TBL] [Abstract][Full Text] [Related]
10. Tracing the origins of glioblastoma by investigating the role of gliogenic and related neurogenic genes/signaling pathways in GBM development: a systematic review.
Shafi O; Siddiqui G
World J Surg Oncol; 2022 May; 20(1):146. PubMed ID: 35538578
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel role of IL-13Rα2 in human Glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway.
Bhardwaj R; Suzuki A; Leland P; Joshi BH; Puri RK
J Transl Med; 2018 Dec; 16(1):369. PubMed ID: 30572904
[TBL] [Abstract][Full Text] [Related]
13. Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature.
Syafruddin SE; Nazarie WFWM; Moidu NA; Soon BH; Mohtar MA
BMC Cancer; 2021 Jul; 21(1):850. PubMed ID: 34301218
[TBL] [Abstract][Full Text] [Related]
14. Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth.
Lee J; Shin YJ; Lee K; Cho HJ; Sa JK; Lee SY; Kim SH; Lee J; Yoon Y; Nam DH
Cancer Res Treat; 2018 Jul; 50(3):1009-1022. PubMed ID: 29129044
[TBL] [Abstract][Full Text] [Related]
15. In silico analysis identified miRNA‑based therapeutic agents against glioblastoma multiforme.
Xiong DD; Xu WQ; He RQ; Dang YW; Chen G; Luo DZ
Oncol Rep; 2019 Apr; 41(4):2194-2208. PubMed ID: 30816530
[TBL] [Abstract][Full Text] [Related]
16. Silencing microRNA-221/222 cluster suppresses glioblastoma angiogenesis by suppressor of cytokine signaling-3-dependent JAK/STAT pathway.
Xu CH; Liu Y; Xiao LM; Chen LK; Zheng SY; Zeng EM; Li DH; Li YP
J Cell Physiol; 2019 Dec; 234(12):22272-22284. PubMed ID: 31106423
[TBL] [Abstract][Full Text] [Related]
17. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
18. Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
Heynckes S; Daka K; Franco P; Gaebelein A; Frenking JH; Doria-Medina R; Mader I; Delev D; Schnell O; Heiland DH
BMC Cancer; 2019 Feb; 19(1):117. PubMed ID: 30709339
[TBL] [Abstract][Full Text] [Related]
19. High expression of RFX4 is associated with tumor progression and poor prognosis in patients with glioblastoma.
Jeong HY; Kim HJ; Kim CE; Lee S; Choi MC; Kim SH
Int J Neurosci; 2021 Jan; 131(1):7-14. PubMed ID: 32075484
[No Abstract] [Full Text] [Related]
20. Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma.
Zhou L; Tang H; Wang F; Chen L; Ou S; Wu T; Xu J; Guo K
Mol Med Rep; 2018 Nov; 18(5):4185-4196. PubMed ID: 30132538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]